 Heat Biologics Inc NASDAQ: HTBX has reported interim data from the Phase 12 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Cos NYSE: BMY Opdivo nivolumab in advanced non-small-cell lung cancer NSCLC patients. The data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting. 